Payment overview · 2025
General Payments
$103.61
6 reported records · 3 companies
Healthcare provider profile · identity verified
Azhar Nisar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DALTON, GA · NPI 1437105046
Verified facts
What the public records show
CMS Open Payments records show Azhar Nisar, MD received $103.61 in general payments during 2025 across 6 reported records.
Sumitomo Pharma America, Inc. accounted for 48.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $50.20 | 48.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.31 | 37.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.10 | 13.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $103.61 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $50.20 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.31 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 754 | 214 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 730 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 457 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 421 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 385 | 104 |
| Omeprazole | Omeprazole | 361 | 82 |
| Losartan Potassium | Losartan Potassium | 350 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 95 |
| Mounjaro | Tirzepatide | 327 | 45 |
| Metformin Hcl | Metformin Hcl | 326 | 101 |
| Montelukast Sodium | Montelukast Sodium | 322 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 305 | 87 |
| Lisinopril | Lisinopril | 296 | 90 |
| Gabapentin | Gabapentin | 295 | 55 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 280 | 93 |
| Ezetimibe | Ezetimibe | 249 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 230 | 53 |
| Furosemide | Furosemide | 228 | 65 |
| Eliquis | Apixaban | 208 | 40 |
| Tramadol Hcl | Tramadol Hcl | 203 | 37 |
| Januvia | Sitagliptin Phosphate | 199 | 46 |
| Prednisone | Prednisone | 190 | 91 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 188 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 49 |
| Alprazolam | Alprazolam | 171 | 17 |
| Potassium Chloride | Potassium Chloride | 163 | 43 |
| Amoxicillin | Amoxicillin | 162 | 98 |
| Vascepa | Icosapent Ethyl | 152 | 46 |
| Famotidine | Famotidine | 150 | 37 |
| Meloxicam | Meloxicam | 147 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 36 |
| Alendronate Sodium | Alendronate Sodium | 140 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 40 |
| Ondansetron Odt | Ondansetron | 131 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 125 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 117 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 105 | 42 |
| Jardiance | Empagliflozin | 104 | 30 |
| Azithromycin | Azithromycin | 103 | 73 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 96 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 22 |
| Diazepam | Diazepam | 92 | 14 |
| Buspirone Hcl | Buspirone Hcl | 90 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 87 | 23 |
| Carvedilol | Carvedilol | 87 | 34 |
| Sertraline Hcl | Sertraline Hcl | 86 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 21 |
| Promethazine Hcl | Promethazine Hcl | 77 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 20 |
| Trazodone Hcl | Trazodone Hcl | 67 | 14 |
| Clonazepam | Clonazepam | 65 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 64 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 14 |
| Simvastatin | Simvastatin | 63 | 12 |
| Allopurinol | Allopurinol | 62 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 21 |
| Ozempic | Semaglutide | 60 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 14 |
| Linzess | Linaclotide | 54 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 18 |
| Finasteride | Finasteride | 53 | 13 |
| Farxiga | Dapagliflozin Propanediol | 51 | 17 |
| Celecoxib | Celecoxib | 50 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 50 | 14 |
| Topiramate | Topiramate | 49 | suppressed |
| Pregabalin | Pregabalin | 48 | suppressed |
| Xarelto | Rivaroxaban | 47 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 45 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 12 |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Lorazepam | Lorazepam | 43 | suppressed |
| Mupirocin | Mupirocin | 43 | 25 |
| Nystatin | Nystatin | 43 | 25 |
| Cephalexin | Cephalexin | 42 | 31 |
| Novolog Flexpen | Insulin Aspart | 42 | 13 |
| Ofloxacin | Ofloxacin | 41 | 27 |
| Spironolactone | Spironolactone | 41 | 13 |
| Glimepiride | Glimepiride | 40 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 20 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 21 |
| Gemtesa | Vibegron | 27 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Leflunomide | Leflunomide | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 19 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 13 |
| Digoxin | Digoxin | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Metronidazole | Metronidazole | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $103.61 · 6 records | Sumitomo Pharma America, Inc. | AIRSUPRA, Dexcom G6 Transmitter, GEMTESA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error